natgillin/translations-raw huggingface dataset:
At week 48, six adolescents in the tenofovir disoproxil fumarate group and one adolescent in the placebo group had significant lumbar spine BMD loss (defined as > 4% loss).
U 48. tjednu 6 adolescenata u skupini koja je primala tenofovirdizoproksilfumarat i jedan adolescent iz skupine koja je primala placebo imali su značajan gubitak BMD-a u lumbalnoj kralježnici (definiran kao gubitak > 4%).
At week 48, the mean increase in CD4+ cell count from baseline was 201.2 x 106 cells/l.
U 48. tjednu srednji porast u broju CD4+ stanica u odnosu na početnu vrijednost bio je 201,2 x 106 stanica/l.
At week 48, the virologic response, defined as the percentage of patients with confirmed plasma viral load < 50 HIV-1 RNA copies/ml, was evaluated in 16 paediatric patients 15 kg to < 20 kg and 5 paediatric patients 10 kg to < 15 kg receiving
U tjednu 48, virološki odgovor, definiran kao postotak bolesnika s potvrđenim virusnim opterećenjem u plazmi < 50 HIV-1 RNK kopija/ml, procijenjen je u 16 pedijatrijskih bolesnika u skupini 15 kg do < 20 kg i 5 pedijatrijskih bolesnika u skupini 10 kg do
At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical remission (DAS28 (CRP) < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Humira monotherapy.
Nakon 52 tjedna liječenja, klinička remisija postignuta je u 42,9% bolesnika liječenih kombinacijom lijeka Humira i metotreksata (DAS28 [CRP] <2,6) u usporedbi s 20,6% bolesnika koji su dobivali monoterapiju metotreksatom, odnosno 23,4% bolesnika koji su dobivali monoterapiju lijekom Humira.
At week 52, patients entered an open label long-term extension in which patients receiving placebo + MTX who had at least 1 tender or swollen joint were switched to Simponi 50 mg + MTX.
52. tjednu, bolesnici su ušli u otvorenu fazu dugotrajnog nastavka tog ispitivanja u kojem se bolesnicima koji su primali placebo i MTX te koji su imali najmanje jedan osjetljivi ili otečeni zglob bili prebačeni na Simponi 50 mg i MTX.
At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 4) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%).
U 52. tjednu, smanjenje HbA1c s 25 mg alogliptina plus metformin (-0,76%, tablica 4) bilo je slično onome postignutom liječenjem s glipizidom (srednja vrijednost doze = 5,2 mg) plus terapija metforminkloridom (srednja vrijednost doze = 1824 mg, -0,73%).
At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 6) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%).
U 52. tjednu, smanjenje HbA1c s 25 mg alogliptina plus metformin (-0,76%, tablica 6) bilo je slično onome postignutom liječenjem s glipizidom (srednja vrijednost doze = 5,2 mg) plus terapija metforminkloridom (srednja vrijednost doze = 1824 mg, -0,73%).
At week 64, Ulunar Breezhaler showed numerical improvement over glycopyrronium (1.95%; p=0.175) and statistical improvement over tiotropium (4.96%; p=0.001).
U 64- om tjednu, Ulunar Breezhaler je pokazao numeričko poboljšanje u odnosu na glikopironij (1,95%; p=0,175) i statističko poboljšanje u odnosu na tiotropij (4,96%; p=0,001).
At week 72, 96% (27/28) of immune-active patients (HBV DNA ≥ 105 copies/ml, serum ALT
72. tjednu, 96% (27/28) imunološki aktivnih pacijenata (HBV DNK ≥ 105 kopija/ml, ALT u serumu
At Week 72, a decline from baseline in percent predicted FVC of ≥10% (a threshold indicative of the risk of mortality in IPF) was seen in 20% of patients receiving Esbriet compared to 35% receiving placebo (Table 2).
U 72. tjednu, pad postotka predviđenog FVC-a za ≥10% u odnosu na početne vrijednosti (granična vrijednost koja ukazuje na rizik od smrti zbog IPF-a) primijećen je u 20% bolesnika koji su primali Esbriet, u usporedbi s 35% bolesnika koji su primali placebo (Tablica 2).
At week 72, overall 88% (46/52) of patients in the tenofovir disoproxil fumarate treatment group and 0% (0/54) of patients in the placebo group had HBV DNA < 400 copies/ml.
U 72. tjednu, ukupno je 88% (46/52) pacijenata u skupini liječenoj tenofovirdizoproksilfumaratom i 0% (0/54) pacijenata u skupini liječenoj placebom imalo HBV DNK < 400 kopija/ml.
At week 8, after a single intravenous induction dose, the change in SES-CD score was greater in the ustekinumab group (n = 155, mean change = -2.8) than in the placebo group (n = 97, mean change = -0.7, p = 0.012).
U 8. tjednu, nakon jedne intravenske uvodne doze, promjena u SES- CD skoru bila je veća u skupini s ustekinumabom (n = 155, srednja vrijednost promjene = -2,8) nego u placebo skupini (n = 97, srednja vrijednost promjena = -0,7, p = 0,012).
At week 8, patients receiving ustekinumab showed statistically significantly greater and clinically meaningful improvements on IBDQ total score and SF-36 Mental Component Summary Score in both UNITI-1 and UNITI-2, and SF-36 Physical Component Summary Score in UNITI-2, when compared to placebo.
U 8. tjednu , bolesnici koji su primali ustekinumab pokazali su statistički značajno veća i klinički značajna poboljšanja ukupnog IBDQ skora i SF-36 zbirnog skora mentalne komponenete i u UNITI-1 i UNITI-2, i SF-36 zbirnog skora fizičke komponenete u UNITI-2, u usporedbi s placebom.
At week 96 the mean changes in CD4 cell count from baseline were +226 x 106 cells/L and +
U 96. tjednu, srednje vrijednosti promjena u broju stanica CD4 od početnih vrijednosti u pacijenata koji su primali emtricitabin/tenofovirdizoproksilfumarat kao osnovni terapijski režim bile su
At Week 96, 88.4% (214/242 patients) maintained HIV-1 RNA < 50 copies/mL after switching to E/C/F/TAF FDC tablet.
Nakon prebacivanja na tabletu s fiksnom kombinacijom E/C/F/TAF, 88,4% (214/242 bolesnika) bolesnika je u 96. tjednu zadržalo HIV-1 RNK < 50 kopija/ml.
At Week 96, 88.4% (214/242 patients) maintained HIV-1 RNA < 50 copies/mL after switching to Genvoya.
Nakon prebacivanja na lijek Genvoya, 88,4% (214/242 bolesnika) bolesnika je u 96. tjednu zadržalo HIV-1 RNK < 50 kopija/ml.
At Week 96, the mean change from baseline in ACTH-stimulated cortisol levels was lower in the rilpivirine arm (+18.4 ± 8.36 nmol/L) than in the efavirenz arm (+54.1 ± 7.24 nmol/L).
U 96. tjednu, srednja promjena od početne vrijednosti razina ACTH-om stimuliranog kortizola bila je manja u ogranku za rilpivirin (+18,4 ± 8,36 nmol/l) nego skupini liječenoj efavirenzom (+54,1 ± 7,24 nmol/l).
At week 96, the mean change from baseline in CD4+ cell count was +228 x 106 cells/l in the rilpivirine arm and +219 x 106 cells/l in the efavirenz arm in the pooled analysis of the ECHO and THRIVE trials [estimated treatment difference (95% CI): 11.3 (-6.8; 29.4)].
U analizi objedinjenih podataka u 96. tjednu ispitivanja ECHO i THRIVE, srednja promjena broja stanica CD4+ u odnosu na početne vrijednosti iznosila je +228 x 106 stanica/l u skupini koja je primala rilpivirin i +219 x 106 stanica/l u skupini koja je primala efavirenz [procijenjena terapijska razlika (95% CI): 11,3 (-6,8; 29,4)].
At Weeks 16 and 24 improvements in parameters of peripheral activity characteristic of psoriatic arthritis (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis) and in the skin manifestations of psoriasis were seen in the apremilast-treated patients.
U 16. i 24. tjednu, u bolesnika liječenih apremilastom opažena su poboljšanja u parametrima periferne aktivnosti karakterističnim za psorijatični artritis (npr. broj otečenih zglobova, broj bolnih/osjetljivih zglobova, daktilitis i entezitis) i u manifestacijama psorijaze na koži.
At weeks 96, 144, 192, 240, 288 and 384, viral suppression, biochemical and serological responses were maintained with continued tenofovir disoproxil fumarate treatment (see Tables 4 and 5 below).
U 96., 144., 192., 240., 288. i 384. tjednu supresija virusa, i biokemijski i serološki odgovori bili su održani uz nastavak liječenja tenofovirdizoproksilfumaratom (vidjeti tablice 4 i 5 niže).
At weeks 96, 144, 192, 240, 288 and 384, viral suppression, biochemical and serological responses were maintained with continued tenofovir disoproxil fumarate treatment (see Tables 5 and 6 below).
U 96., 144., 192., 240., 288. i 384. tjednu supresija virusa, i biokemijski i serološki odgovori bili su održani uz nastavak liječenja tenofovirdizoproksilfumaratom (vidjeti tablice 5 i 6 niže).
At ≥ 6 times the human clinical exposure in adult ITP patients at 75 mg/day and 3 times the human clinical exposure in adult HCV patients at 100 mg/day, based on AUC, cataracts were observed in mice after 6 weeks and rats after 28 weeks of dosing.
Pri ≥ 6 puta većoj izloženosti od kliničke izloženosti odraslih bolesnika s ITP-om pri dozi od 75 mg/dan i 3 puta većoj kliničkoj izloženosti od odraslih bolesnika s HCV-om pri dozi od 100 mg/dan, mjerenoj AUC-om, katarakta je zamijećena u miševa nakon 6 tjedana i štakora nakon 28 tjedana primjene lijeka.
Ataluren enables ribosomal readthrough of mRNA containing such a premature stop codon, resulting in production of a full-length protein.
Ataluren omogućuje ribosomalnu translaciju mRNK preko preuranjenog stop-kodona , što rezultira sintezom proteina pune dužine.
Ataluren is metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes, predominantly UGT1A9 in liver and intestine.
Ataluren se metabolizira konjugacijom putem enzima uridin difosfat glukuronoziltransferaze (UGT), predominatno UGT1A9 u jetri i crijevima.
Ataluren should not be co-administered with intravenous aminoglycosides, based on cases of decreased renal function observed in a clinical trial in patients with nmCF (see section 4.3 ).
Ataluren se ne smije primjenjivati istovremeno s intravenskim aminoglikozidima zbog slučajeva smanjenja funkcije bubrega uočenih u kliničkom ispitivanju u bolesnika oboljelih od cistične fibroze (CF) s besmislenom mutacijom (vidjeti dio 4.3).
Ataxia
ataksija
Ataxia Dizziness
ataksija, omaglica,
Ataxia Dizziness Memory impairment Somnolence
ataksija, omaglica, oslabljeno pamćenje, somnolencija
Ataxia Paresthesia Vertigo Sleepiness
Ataksija Parestezija Vertigo Pospanost
Ataxia, Convulsion, Headache, High-pitched crying, Hyperkinesia, Hypersomnia, Lethargy, Tremor
ataksija, konvulzije, glavobolja, vrištavo plakanje, hiperkinezija, hipersomnija, letargija, tremor
Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy
ataksija, poremećaj koordinacije, tremor, dizartrija, amnezija, poremećaj pamćenja, poremećaj pažnje, parestezija, hipoestezija, sedacija, poremećaj ravnoteže, letargija
ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, transient ischaemic attack, posterior reversible encephalopathy syndrome
ataksija, poremećaj pažnje, hepatalna encefalopatija, gubitak svijesti, poremećaj govora, prolazni ishemijski napadaj, sindrom posteriorne reverzibilne encefalopatije
Atazanavir
Gospina
Atazanavir
lijeka.
atazanavir
Mehanizam:
atazanavir
tonavir
Atazanavir (300 mg once daily)
Atazanavir (300 mg jedanput na
Atazanavir (pm):
atazanavir (popodne):
Atazanavir (pm): all administered with food
Atazanavir (pm): svi primijenjeni s
Atazanavir (pm): AUC: ↔* (↓ 9 to ↑ 10)
AUC: ↔* (↓ 9 do ↑ 10)
Atazanavir + cobicistatf (n = 344)
Atazanavir + kobicistatf (n = 344)
atazanavir /ritonavir (raltegravir 400 mg Twice Daily)
atazanavir/ritonavir (raltegravir 400 mg dvaput na dan)
atazanavir /ritonavir /lamivudine
atazanavir/ritonavir/lamivudin
atazanavir /ritonavir /raltegravir (raltegravir 400 mg Twice Daily)
atazanavir/ritonavir/raltegravir (raltegravir 400 mg dvaput na dan)
atazanavir 300 mg and ritonavir 100 mg once daily
atazanavir 300 mg i ritonavir 100 mg jedanput na dan
Atazanavir 300 mg once daily
atazanavir 300 mg jednom dnevno
atazanavir 300 mg with ritonavir 100 mg
atazanavir 300 mg s ritonavirom 100 mg
Atazanavir 300 mg/ritonavir 100 mg once daily (daclatasvir 20 mg once daily)
atazanavir 300 mg/ritonavir 100 mg jedanput na dan (daklatazvir 20 mg jedanput na dan)
Atazanavir and fluconazole concentrations were not significantly modified when atazanavir/ritonavir was co- administered with fluconazole.
Koncentracije atazanavira i flukonazola nisu se značajno promijenile kada se atazanavir/ritonavir primjenjivao istodobno s flukonazolom.
atazanavir and ritonavir
atazanavir i ritonavir
atazanavir and ritonavir lopinavir/ritonavir
atazanavirom i ritonavirom lopinavirom/ritonavirom
atazanavir and ritonavir to
atazanavir (pm):
Atazanavir AUC ↓20% (↓35% ↓3%) Atazanavir Cmax ↓19% (↓34% ↔0.2%) Atazanavir Cmin ↓ 31 % (↓46 % ↓13%)
Atazanavir Cmin ↓ 31 % (↓46 % ↓13%)
Atazanavir boosted with
Atazanavir pojačan
atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11%
atazanavir Cmin ↑ 52
atazanavir concentrations was
koncentracije atazanavira kod
atazanavir concentrations was
na koncentracije atazanavira.
Atazanavir concentrations were
Koncentracije atazanavira jako su
atazanavir given alone, due to both
bila povišena kad se atazanavir davao
Atazanavir increases
Atazanavir povisuje koncentracije
atazanavir is 300 mg with
atazanavira je 300 mg s ritonavirom
atazanavir is 300 mg,
atazanavira je 300 mg bez
Atazanavir is an inhibitor of CYP3A4 and UGT1A1.
Atazanavir je inhibitor CYP3A4 i UGT1A1.
Atazanavir or darunavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Koncentracije atazanavira ili darunavira u plazmi mogu se smanjiti kao posljedica smanjenja koncentracija kobicistata u plazmi što može uzrokovati gubitak terapijskog učinka i razvoj rezistencije.
Atazanavir plasma trough concentrations were approximately 2-fold higher during the postpartum period when compared to those observed historically in HIV infected non-pregnant patients. b Cmin is concentration 24 hours post-dose.
Najniže koncentracije atazanavira u plazmi bile su približno dvostruko više tijekom postpartalnog razdoblja u usporedbi s onima prethodno opaženima u bolesnica zaraženih HIV-om koje nisu bile trudne. b Cmin je koncentracija 24 sata nakon doze.
atazanavir which may be
atazanaviru, što može biti
Atazanavir with cobicistatf (n = 344)
Atazanavir s kobicistatomf (n = 344)
Atazanavir with ritonavir or cobicistat Darunavir with ritonavir or cobicistat1 Lopinavir with ritonavir
atazanavir s ritonavirom ili kobicistatom darunavir s ritonavirom ili kobicistatom1 lopinavir s ritonavirom
Atazanavir with ritonavirf (n = 348)
Atazanavir s ritonaviromf (n = 348)
Atazanavir  (historical controls) (inhibition of UGT1A1 and CYP3A enzymes)
atazanavir  (kontrole iz prethodnih ispitivanja) (inhibicija enzima UGT1A1 i CYP3A)
Atazanavir, darunavir or boceprevir plasma concentrations may decrease upon co-administration.
Koncentracije atazanavira, darunavira ili boceprevira u plazmi mogu se smanjiti uz istovremenu primjenu.
atazanavir, darunavir, delavirdine, efavirenz, etravirine, fosamprenavir, indinavir, lopinavir, nelfinavir, nevirapine, ritonavir, saquinavir or tipranavir
atazanavir, darunavir, delavirdin, efavirenz, etravirin, fosamprenavir, indinavir, lopinavir, nelfinavir, nevirapin, ritonavir, sakvinavir ili tipranavir
Atazanavir, dosed 1 hr after
Atazanavir, primijenjen 1 sat
Atazanavir, efavirenz, etravirine, fosamprenavir, indinavir, nevirapine, ritonavir, saquinavir
atazanavir, efavirenz, etravirin, fosamprenavir, indinavir, nevirapin, ritonavir, sakvinavir
Atazanavir, saquinavir (used to treat HIV infection)
Atazanavir, sakvinavir (koriste se za liječenje HIV infekcije)
Atazanavir, simultaneous
Atazanavir, primjena u isto
atazanavir, the dose of Vitekta
atazanavirom, doza lijeka Vitekta
atazanavir, the net effect of
atazanavira/ritonavira je sniženje
atazanavir.
Atazanavir
atazanavir.
djelotvornost atazanavira.
Atazanavir/
atazanavir
Atazanavir/ ritonavir/Efavirenz
atazanavir/ritonavir/efavirenz
Atazanavir/cobicistat (300 mg/150 mg once daily), tenofovir alafenamide (10 mg)
Atazanavir/kobicistat (300 mg/150 mg jedanput na dan), tenofoviralafenamid (10 mg)
Atazanavir/r 300/100mg: Atazanavir/r AUC  0.58 (0.48-0.71)
Atazanavir/r 300/100mg: Atazanavir/r AUC  0,58 (0,48-0,71)
Atazanavir/r 400/100mg: Atazanavir/r AUC ↓ 0.81 (0.65-1.02)
Atazanavir/r 400/100mg: Atazanavir/r AUC  0,81 (0,65-1,02)
Atazanavir/r 400/100mg: Atazanavir/r AUC  0.81 (0.65-1.02)
Atazanavir/r 400/100mg: Atazanavir/r AUC  0,81 (0,65-1,02)
Atazanavir/r AUC ↓ 0.58 (0.48-0.71)
Atazanavir/r AUC  0,58 (0,48-0,71)
Atazanavir/r Cmax ↓ 0.72 (0.60-0.86)
Atazanavir/r Cmax  0,72 (0,60-0,86)
Atazanavir/r Cmax  0.72 (0.60-0.86)
Atazanavir/r Cmax  0,72 (0,60-0,86)
Atazanavir/r Cmin ↓ 0.28 (0.20-0.40)
Atazanavir/r Cmin  0,28 (0,20-0,40)
Atazanavir/r Cmin ↓ 0.41 (0.27-0.60)
Atazanavir/r Cmin  0,41 (0,27-0,60)
Atazanavir/r Cmin  0.28 (0.20-0.40)
Atazanavir/r Cmin  0,28 (0,20-0,40)
Atazanavir/r Cmin  0.41 (0.27-0.60)
Atazanavir/r Cmin  0,41 (0,27-0,60)
atazanavir/ritonavir
akvinavira/ritonavira ili
Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.) + Emtricitabine/Tenofovir disoproxil fumarate (200 mg/300 mg q.d.)1
(300 mg q.d./100 mg q.d.) + emtricitabin/tenofovirdizoproksil- fumarat (200 mg/300 mg q.d.)1
Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.) + Emtricitabine/Tenofovir disoproxil fumarate (200 mg/300 mg q.d.)1
Atazanavir/Ritonavir (300 mg q.d./100 mg q.d.) + Emtricitabin/tenofovirdizoproksilfuma rat (200 mg/300 mg q.d.)1
atazanavir/ritonavir 300/100 mg
atazanavirom/ritonavirom
atazanavir/ritonavir 300/100 mg once daily
atazanavir/ritonavir 300/100 mg
atazanavir/ritonavir and induction
atazanavir/ritonavira te indukcija
atazanavir/ritonavir can be
atazanavir/ritonavir mogu se
Atazanavir/Ritonavir has been
Pokazalo se da
atazanavir/ritonavir in the absence of
atazanavira/ritonavira u odsutnosti
atazanavir/ritonavir is a decrease in
atazanavira/ritonavira je sniženje
Atazanavir/ritonavir is not effective in viral strains harbouring multiple mutations of resistance.
Kombinacija atazanavir/ritonavir nije djelotvorna kod sojeva virusa koji nose višestruke mutacije za rezistenciju.
atazanavir/ritonavir with
atazanavira/ritonavira s
atazanavir/ritonavir, darunavir/ritonavir, or
darunavir/ritonavir ili lopinavir/ritonavir.
Atazanavir/ritonavir/Efavirenz (400 mg q.d./100 mg q.d./600 mg q.d., all administered with food)
(400 mg q.d./100 mg q.d./600 mg q.d., svi se primjenjuju s hranom)
Atazanavir/Ritonavir/Rilpivirine
Atazanavir/ritonavir/rilpivirin
Atazanavir/ritonavir/Tenofovir disoproxil fumarate (300 mg q.d./100 mg q.d./300 mg q.d.)
atazanavir/ritonavir/tenofovirdizoproksil fumarat (300 mg q.d./100 mg q.d./300 mg q.d.)
Atazanavir/ritonavir: Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir in combination with Atripla.
Atazanavir/ritonavir: Nije dostupno dovoljno podataka za određivanje preporučene doze za atazanavir/ritonavir kada se primjenjuje u kombinaciji s Atriplom.
Atazanavir:
dan)
Atazanavir:
tenofovirdizoproksil
Atazanavir: Cmax  24%* Atazanavir: AUC  22%* Atazanavir: Cmin*
Atazanavir: Cmax  24%* Atazanavir: AUC 22%* Atazanavir: Cmin
Atazanavir: comparison of
Atazanavir: usporedba
ATC code: A10A B04 The primary activity of insulin lispro is the regulation of glucose metabolism.
ATK oznaka: A10A B04 Primarno djelovanje inzulina lispro je regulacija metabolizma glukoze.
ATC Code: A10A C04.
ATK oznaka: A10AC04.
ATC Code: A10A D04.
ATK oznaka: A10A D04.
ATC code: A10AD01.
ATK oznaka: A10AD01.
ATC code: A10BX07
ATK oznaka: A10BX07.
ATC code: A10BX13
ATK oznaka: A10BX13
ATC code: B01A B05 Mechanism of action
ATK oznaka: B01A B05 Mehanizam djelovanja
ATC code: B02BD04
ATK oznaka: B02BD04
ATC code: B02BD04.
ATK oznaka: B02BD04.
ATC code: B02BD06 von Willebrand disease
ATK oznaka: B02BD06 Von Willebrandova bolest
ATC code: C10AX12 Mechanism of action
ATK oznaka: C10AX12 Mehanizam djelovanja
ATC code: C10AX13 Mechanism of action
ATK oznaka: C10AX13 Mehanizam djelovanja
ATC code: D06AX13
ATK oznaka: D06AX13
ATC code: G03XC01 Mechanism of action and Pharmacodynamic effect
Mehanizam djelovanja i farmakodinamički učinak
ATC code: J07BA02 Mechanism of action
ATK oznaka: J07BA02 Mehanizam djelovanja
ATC code: L01BA01
ATK oznaka: L01BA01
ATC code: L01XC18 Mechanism of action
ATK oznaka: L01XC18 Mehanizam djelovanja
ATC code: L01XE31
ATK oznaka: L01XE31.
ATC code: N05AX13 TREVICTA contains a racemic mixture of (+)- and (-)-paliperidone.
ATK oznaka: N05AX13 TREVICTA sadrži racemičnu smjesu (+) i (-) paliperidona.
ATC code: N05AX13 Xeplion contains a racemic mixture of (+)- and (-)-paliperidone.
ATK oznaka: N05AX13 Xeplion sadrži racemičnu smjesu (+) i (-) paliperidona.
ATC code: not yet assigned.
ATK oznaka: nije još dodijeljena
ATC code: not yet assigned.
ATK oznaka: nije još dodijeljena.
ATC code: S01G X 06.
ATK oznaka: S01G X 06
ATC code: S01GX 09
ATK oznaka: S01GX 09
ATC vet code : QI07AO01.
Farmakodinamička svojstva
ATC vet code: QI04AA02.
ATC vet kod: QI04AA02.
ATC vet code: QI09AB08.
ATC vet kod: QI09AB08.
ATC-vet code: QI05AL01
ATCvet kod: QI05AL01
ATCvet code: QD11AH90.
ATCvet kod: QD11AH90
ATCvet code: QI06AL01.
ATCvet kod: QI06AL01
ATCvet code: QI07A
ATCvet kod: QI07A
ATCvet code: QI07AD08.
ATCvet kod: QI07AD08.
ATCvet code: QI07AJ.
ATCvet kod: QI07AJ.
ATCvet code: QI09 AD01.
ATCvet kod: QI09AD01
ATCvet code: QI09AA07.
ATCvet code: QI09AA07
ATCvet code: QI09AL.
ATCvet kod: QI09AL
ATCvet code: QJ01FA96.
ATCvet kod: QJ01FA96
ATCvet code: QL03AX.
ATCvet kod: QL03AX.
ATCvet code: QM01AC06.
ATCvet kod: QM01AC06
ATCvet code: QM01AH91.
ATCvet kod: QM01AH91
ATCvet code: QP52AA51.
ATCvet kôd: QP52AA51
ATCvet code: QP52AC13.
ATCvet kod: QP52AC13
ATCvet code: QP53BX04.
ATCvet broj: QP53BX04.
ATCvet code: QP54AA54.
ATC vet kod: QP54AA54
ATCvet code: QP54AB51.
ATCvet broj: QP54AB51.
ATCvet code: Sheep: QI04AA02
ATCvet broj: Ovce: QI04AA02
ATCvet: QM01AC06.
ATCvet kod: QM01AC06.
atelectasis, pharyngeal oedema, pneumonitis
atelektaza, faringealni edem, pneumonitis
Atelectasisa
Atelektazaa
aTerm(s) included based on postmarketing experience. c.
a Pojmovi uključeni na temelju postmarketinškog iskustva.
Athe median duration of follow-up time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Pri medijanu vremena praćenja od 77 mjeseci dokazano je značajno poduljenje preživljenja bez znakova bolesti u u TAC skupini u usporedbi sa bolesnicima iz FAC skupine.
Athe median follow-up time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Pri medijanu vremena praćenja od 77 mjeseci dokazano je značajno poduljenje preživljenja bez znakova bolesti u TAC skupini u usporedbi sa bolesnicima iz FAC skupine.
aThe table shows adverse reactions identified from up to 24-week (short-term) data regardless of glycaemic rescue, except those marked with §, for which adverse reaction and frequency categories are based on information from the metformin Summary of Product Characteristics available in the European Union. bSee corresponding subsection below for additional information. cVulvovaginitis, balanitis and related genital infections includes, e.g. the predefined preferred terms: vulvovaginal mycotic infection, vaginal infection, balanitis, genital infection fungal, vulvovaginal candidiasis, vulvovaginitis,
aTablica prikazuje nuspojave utvrđene na temelju podataka do najviše 24 tjedna liječenja (kratkoročni podaci) neovisno o lijekovima za hitnu regulaciju glikemije, osim nuspojava označenih znakom §, za koje se kategorije nuspojava i učestalosti temelje na informacijama preuzetima iz Sažetka opisa svojstava lijeka za metformin dostupan u Europskoj uniji. bZa dodatne informacije vidjeti odgovarajući odlomak u nastavku. cVulvovaginitis, balanitis i srodne genitalne infekcije uključuju npr. unaprijed određene preferirane pojmove: vulvovaginalna gljivična infekcija, vaginalna infekcija, balanitis, gljivična genitalna
Athens
Athens GREECE
Athens, Attiki 15771 Greece
Athens, Attiki 15771 Grčka
Atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence
Ateroskleroza kao što je infarkt miokarda, atrioventrikularni blok, insuficijencija trikuspidalne valvule